GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a phase 3 trial involving patients with complicated urinary tract infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback